Mount Sinai Cardiovascular Institute, New York, New York 10029, USA.
JAMA. 2011 Feb 9;305(6):585-91. doi: 10.1001/jama.2011.99.
Several small studies have suggested that cardiac enzyme elevation in the 24 hours following coronary artery bypass graft (CABG) surgery is associated with worse prognosis, but a definitive study is not available. Also, the long-term prognostic impact of small increases of perioperative enzyme has not been reported.
To quantify the relationship between peak post-CABG elevation of biomarkers of myocardial damage and early, intermediate-, and long-term mortality, including determining whether there is a threshold below which elevations lack prognostic significance.
Studies (randomized clinical trials or registries) of patients undergoing CABG surgery in which postprocedural biomarker and mortality data were collected and included. A search of the PubMed database was performed in July 2008 using the search terms coronary artery bypass, troponin, CK-MB, and mortality.
Studies evaluating mortality and creatine kinase (CK-MB), troponin, or both were included. One study investigator declined to participate and 3 had insufficient data.
Two independent reviewers determined study eligibility. The principal investigator from each eligible study was contacted to request his/her participation. Once institutional review board approval for the use of these data for this purpose was obtained, we requested patient-level data from each source. Data were examined to ensure that cardiac markers had been measured within 24 hours after CABG surgery, key baseline covariates, and mortality were available.
A total of 18,908 patients from 7 studies were included. Follow-up varied from 3 months to 5 years. Mortality was found to be a monotonically increasing function of the CK-MB ratio. The 30-day mortality rates by categories of CK-MB ratio were 0.63% (95% confidence interval [CI], 0.36%-1.02%) for 0 to <1, 0.86% (95% CI, 0.49%-1.40%) for 1 to <2, 0.95% (95% CI, 0.72%-1.22%) for 2 to <5, 2.09% (95% CI, 1.69%-2.57%) for 5 to <10, 2.78% (95% CI, 2.12%-3.58%) for 10 to <20, and 7.06% (95% CI, 5.46%-8.96%) for 20 to ≥40. Of the variables considered, the CK-MB ratio was the strongest independent predictor of death to 30 days and remained significant even after adjusting for a wide range of baseline risk factors (χ(2) = 143, P < .001; hazard ratio [HR] for each 5 point-increment above the upper limits of normal [ULN] = 1.12; 95% CI, 1.10-1.14). This result was strongest at 30 days, but the adjusted association persisted from 30 days to 1 year (χ(2) = 24; P < .001; HR for each 5-point increment above ULN = 1.17; 95% CI, 1.10-1.24) and a trend was present from 1 year to 5 years (χ(2) = 2.8; P = .10; HR for each 5-point increment above ULN = 1.05; 95% CI, 0.99-1.11). Similar analyses using troponin as the marker of necrosis led to the same conclusions (χ(2) = 142 for 0-30 days and χ(2) = 40 for 30 days to 6 months, both P < .001; HR for each 50 points above the ULN = 1.28; 95% CI, 1.23-1.33 and 1.15; 95% CI, 1.10-1.21, respectively).
Among patients who had undergone CABG surgery, elevation of CK-MB or troponin levels within the first 24 hours was independently associated with increased intermediate- and long-term risk of mortality.
几项小型研究表明,冠状动脉旁路移植术(CABG)后 24 小时内心脏酶升高与预后较差相关,但目前尚无明确的研究结果。此外,围手术期小幅度的酶升高对长期预后的影响尚未报道。
定量分析术后心肌损伤标志物峰值升高与早期、中期和长期死亡率之间的关系,包括确定升高是否缺乏预后意义的阈值。
检索了 2008 年 7 月在 PubMed 数据库中以“冠状动脉旁路”、“肌钙蛋白”、“CK-MB”和“死亡率”为检索词的随机临床试验或注册研究。
纳入评估死亡率和肌酸激酶(CK-MB)、肌钙蛋白或两者的研究。一位研究人员拒绝参与,另外 3 项研究的数据不足。
两位独立的审查员确定了研究的合格性。联系了每项合格研究的主要研究者,以邀请其参与。一旦获得使用这些数据的机构审查委员会批准,我们就从每个来源请求患者水平的数据。检查数据以确保心脏标志物是在 CABG 手术后 24 小时内测量的,同时还获得了关键的基线协变量和死亡率。
来自 7 项研究的 18908 名患者被纳入分析。随访时间从 3 个月到 5 年不等。死亡率与 CK-MB 比值呈单调递增函数关系。根据 CK-MB 比值的分类,30 天死亡率分别为:0-<1 为 0.63%(95%置信区间,0.36%-1.02%),1-<2 为 0.86%(95%置信区间,0.49%-1.40%),2-<5 为 0.95%(95%置信区间,0.72%-1.22%),5-<10 为 2.09%(95%置信区间,1.69%-2.57%),10-<20 为 2.78%(95%置信区间,2.12%-3.58%),20-≥40 为 7.06%(95%置信区间,5.46%-8.96%)。在考虑的变量中,CK-MB 比值是死亡至 30 天的最强独立预测因素,即使在调整了广泛的基线风险因素后仍然具有统计学意义(χ(2) = 143,P<.001;每增加 5 个高于正常值上限[ULN]的点,风险比[HR]为 1.12;95%置信区间,1.10-1.14)。这一结果在 30 天时最强,但调整后的关联在 30 天至 1 年(χ(2) = 24;P<.001;每增加 5 个 ULN 点的 HR 为 1.17;95%置信区间,1.10-1.24)和 1 年至 5 年(χ(2) = 2.8;P =.10;每增加 5 个 ULN 点的 HR 为 1.05;95%置信区间,0.99-1.11)时仍然存在。使用肌钙蛋白作为坏死标志物进行的类似分析得出了相同的结论(0-30 天为 χ(2) = 142,30 天至 6 个月为 χ(2) = 40,均 P<.001;每增加 50 个 ULN 点的 HR 为 1.28;95%置信区间,1.23-1.33 和 1.15;95%置信区间,1.10-1.21)。
在接受冠状动脉旁路移植术的患者中,术后 24 小时内 CK-MB 或肌钙蛋白水平升高与中期和长期死亡率增加独立相关。